Aurora: Making bespoke base editing commercially viable

Aurora is trying to turn the baby KJ treatment into a repeatable business model by using base editing to industrialize bespoke genetic fixes for phenylketonuria, starting with a mutation basket trial that leans hard on FDA’s evolving gene editing framework. 

Aurora Therapeutics Inc., co-founded by CRISPR pioneer Jennifer Doudna and Fyodor Urnov, one of the scientists behind the individualized baby KJ gene-editing treatment, is led by CEO Edward Kaye, the former chief of biochemical genetics at Children’s Hospital of Philadelphia and a Genzyme veteran who has led teams to eight approvals. ...